Observational study on the identification of subclinical biomarkers for anticancer drug-induced cardiac dysfunction

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030230492

Enrollment

300

Registered

2023-12-06

Start date

2023-04-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

all cancer patients cancer

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Among patients diagnosed with cancer and receiving treatment, patients who meet all of the inclusion criteria below and do not fall under any of the exclusion criteria are targeted. Cancer patients who are scheduled to receive doxorubicin anticancer treatment Patients who have given written consent. Patients with preserved cardiac function (LVEF>53%) Patients with a predicted prognosis of 6 months or more at the time of initial examination Over 20 years old at the time of obtaining consent (regardless of gender)

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Correlation between decreased cardiac function (LVEF<53% or 10% lower than LVEF before anticancer drug treatment) and changes in each biomarker in echocardiography	—

Secondary

Measure	Time frame
Relationship between heart failure signs (orthopnea, cyanosis, lower leg edema) and changes in biomarkers Relationship between diastolic dysfunction in cardiac ultrasound examination and changes in biomarkers Relationship between patient medical history and changes in biomarkers	—

Contacts

Public ContactMasaaki Shoji

National Cancer Center

mshoji@ncc.go.jp+81-3-3542-2511

Outcome results